Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
According to a 2016 study, the mean price of insulin increased nearly 3-fold between 2002 and 2013.
TYPE 2 DIABETES ADVISOR
Type 2 Diabetes Advisor
Feature
-
-
The Obesity Paradox in Diabetes: Conceptual and Clinical Approaches
Overweight and obesity are established risk factors for the development of metabolic diseases, including diabetes, hypertension, dyslipidemia, and cardiovascular disease. -
Type 2 Diabetes and Alzheimer Disease: What’s the Connection?
Findings suggest that insulin resistance and deficiency may increase the risk of Alzheimer disease via their influence on brain function. -
Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
Environmental causes of T2D and other metabolic disorders are often overlooked; a new body of evidence, however, is changing the clinical thinking about mitigating these effects on those at high risk of T2D. -
Managing Diabetes Risk in Polycystic Ovary Syndrome
Insulin resistance contributes to the increased risk of type 2 diabetes in individuals with polycystic ovary syndrome. -
SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
Dr Bush discusses the combination of SGLT2 inhibitors and GLP-1 receptor agonist for the treatment of type 2 diabetes. -
Medication Adherence in Youth With Type 2 Diabetes: Latest Insights
Barriers and strategies for medication adherence in youth with type 2 diabetes were found to be similar to those observed in youth with other chronic pediatric conditions. -
Is There a Role for Precision Nutrition in the Management of Type 2 Diabetes?
Emerging evidence shows promise regarding the potential role of precision nutrition in the prevention and management of T2D. However, considerably more research is needed before this approach can be widely applied for these purposes.
LATEST CONTENT
Modifiable Risk Factors Associated With Prediabetes and T2D Following a Coronary Event
Investigators sought to identify sociodemographic, medical, and psychosocial factors associated with prediabetes and type 2 diabetes.
Predictive Capabilities of Urine Metabolites on Progressive Chronic Kidney Disease in T2D
Investigators examine whether urine metabolites in the tricarboxylic acid cycle can independently predict the risk for CKD progression in individuals with type 2 diabetes.
Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
The use of liraglutide in patients with type 2 diabetes did not increase the risk for diabetes-related foot ulcers.
Bariatric Surgery Reduces Microvascular Disease in Type 2 Diabetes
Investigators sought to determine whether bariatric surgery was associated with lower incidence of microvascular disease for patients with T2D and severe obesity.
Inflammation and Endothelial Stress Associated With CV Risk in Type 2 Diabetes With Manifest CVD
The risk for cardiovascular events in patients with type 2 diabetes without manifest cardiovascular disease is primarily related to the severity of atherosclerosis.
Journal Articles
Stähli BE, Nozza A, Schrieks IC, et al. Homeostasis model assessment of insulin resistance and survival in patients with diabetes and acute coronary syndrome.
J Clin Endocrinol Metab. 2018 ;103(7):2522-2533.
J Clin Endocrinol Metab. 2018 ;103(7):2522-2533.
van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.
Cardiovasc Diabetol. 2018; ;17(1):94.
Cardiovasc Diabetol. 2018; ;17(1):94.
Guja C, Frías JP, Somogyi A, et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Diabetes Obes Metab. 2018; 20(7):1602-1614.
Diabetes Obes Metab. 2018; 20(7):1602-1614.
Bullard KM, Cowie CC, Lessem SE, et al. Prevalance of diagnosed diabetes in adults by diabetes type – United States, 2016.
MMWR Morb Mortal Wkly Rep. 2018;67(12):359-361.
MMWR Morb Mortal Wkly Rep. 2018;67(12):359-361.
Heinzel A, Kammer M, Mayer G, et al. Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes
[published online July 6, 2018]. Diabetes Care. doi: 10.2337/dc18-0532
[published online July 6, 2018]. Diabetes Care. doi: 10.2337/dc18-0532
Perkovic V, Zeeuw D, Mahaffey KW et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
[published online June 21, 2018]. Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(18)30141-4
[published online June 21, 2018]. Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(18)30141-4
Patient Education Materials
Related Links (set in alphabetical order):
- American Diabetes Association: Type 2 Diabetes
- National Institute of Diabetes and Digestive and Kidney Diseases: Diabetes Discoveries & Practice Blog
- National Institute of Diabetes and Digestive and Kidney Diseases: Game Plan for Preventing Type II Diabetes
- National Institute of Diabetes and Digestive and Kidney Diseases: Guiding Principles for Diabetes Care
- National Institute of Diabetes and Digestive and Kidney Diseases: Practice Transformation for Physicians and Health Care Teams
Want to read more?
Please login or register first to view this content.
Next post in Type 2 Diabetes Advisor
